drugset / Trial / NCT07528027
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;
Timeline
- Start
- 2026-05-29
- Primary completion
- 2027-12
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS-7535 | Small molecule | — | — |
Indications
No indication recorded.